Condition (MeSH)
Ehlers-Danlos Syndrome, Type IV
ClinicalTrials.gov lists 16 trials for Ehlers-Danlos Syndrome, Type IV or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
16 of the 16 trials are tagged with Ehlers-Danlos Syndrome, Type IV itself; the rest are tagged with a narrower condition beneath it.
When did Ehlers-Danlos Syndrome, Type IV trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 2 |
| 2022 | 2 |
| 2016 | 2 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 1 |
| 2010 | 1 |
| 2003 | 1 |
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ehlers-Danlos Syndrome, Type IV trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 3 | 3 |
| Phase 4 | 1 |
| Not applicable | 4 |
| Observational | 8 |
How many Ehlers-Danlos Syndrome, Type IV trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 5 |
| Active, not recruiting | 2 |
| Completed | 6 |
| Suspended | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ehlers-Danlos Syndrome, Type IV trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Acer Therapeutics Inc. | 1 |
| Aytu BioPharma, Inc. | 1 |
| Institut National de la Santé Et de la Recherche Médicale, France | 1 |
Which drugs are being tested for Ehlers-Danlos Syndrome, Type IV? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Celiprolol | 1 |
| IRBESARTAN | 1 |
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| ACER-002 (celiprolol) 200 mg BID | 1 |
| Control (placebo) group | 1 |
| Enzastaurin (LY317615) monohydronchloride | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Ehlers-Danlos Syndrome, Type IV? (1)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Efficacy of Irbesartan in Celiprolol-Treated Patients With Vascular Ehlers-Danlos Syndrome. | Circulation | 2025 | No |
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Vascular Ehlers-Danlos syndrome | Point prevalence | 1-9 / 100 000 | Worldwide | Not stated | Exact |
| Vascular Ehlers-Danlos syndrome | Point prevalence | 1-9 / 100 000 | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Vascular Ehlers-Danlos syndrome | 286 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Vascular Ehlers-Danlos syndrome | 286 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.